ART26.12
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C29H28O6 |
| Molar mass | 472.537 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ART26.12 is an experimental drug that acts as a selective inhibitor of the enzyme FABP5, which usually breaks down endocannabinoids such as anandamide. ART26.12 thereby boosts endocannabinoid levels and has analgesic effects, showing efficacy against atypical pain syndromes such as hyperalgesia and allodynia. It is being researched as a potential treatment for neuropathy which can occur as a side effect of some kinds of chemotherapy, as well as showing activity against psoriasis.[1][2][3][4]
References
[edit]- ^ Warren G, Osborn M, Tsantoulas C, David-Pereira A, Cohn D, Duffy P, et al. (July 2024). "Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective in Oxaliplatin-Induced Peripheral Neuropathy". The Journal of Pain. 25 (7): 104470. doi:10.1016/j.jpain.2024.01.335. PMID 38232863.
- ^ Warren WG, Osborn M, Duffy P, Yates A, O'Sullivan SE (October 2024). "Potential safety implications of fatty acid-binding protein inhibition". Toxicology and Applied Pharmacology. 491: 117079. Bibcode:2024ToxAP.49117079W. doi:10.1016/j.taap.2024.117079. PMID 39218163.
- ^ Warren WG, Osborn M, David-Pereira A, Tsantoulas C, Xue W, Yates A, et al. (February 2025). "ART26.12, a novel fatty acid-binding protein 5 inhibitor, shows efficacy in multiple preclinical neuropathy models". European Journal of Pain. 29 (2). London, England: e4718. doi:10.1002/ejp.4718. PMC 11671339. PMID 39188040.
- ^ Warren WG, Osborn M, Yates A, O'Sullivan SE (April 2025). "ART26.12, a fatty acid-binding protein 5 inhibitor, shows efficacy in preclinical psoriasis models". The Journal of Investigative Dermatology. doi:10.1016/j.jid.2025.03.026. PMID 40210114.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |